Skip to the content
Altai Oncology - Softwarelogo darklogo light
  • Library
  • Articles
  • Patient Education
  • F.A.Q.
  • Contact Us
Altai Oncology - Softwarelogo darklogo light
Uterine Cancer

New Protocol: Durvalumab with CARBOplatin and PACLitaxel for Endomterial Cancer

Ulas D. Bayraktar, MD
2024-06-21
Uterine Cancer

New Indication: Selinexor for Maintenance in Advanced Endometrial Cancer

Ulas D. Bayraktar, MD
2023-09-23
Uterine Cancer

New Protocol: Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma

Ulas D. Bayraktar, MD
2023-08-20
Uterine Cancer

New Protocol: Pembrolizumab with Chemotherapy in Advanced Endometrial Cancer

Ulas D. Bayraktar, MD
2023-04-14
Uterine Cancer

New Indication: Trastuzumab Deruxtecan for her2-Expressing Advanced Uterine Cancer

Ulas D. Bayraktar, MD
2023-04-14
Uterine Cancer

New Drug: Dostarlimab for Endometrial Cancer

Ulas D. Bayraktar, MD
2023-03-15
  • Library
  • F.A.Q.
  • Contact Us

Privacy Policy

Altai, Inc (USA)

30 N Gould St, Ste 6801

Sheridan, WY, 82801, USA

Phone: +1 (978) 393 0042

Altay Tıp Sağlık Yazılım AŞ (Türkiye)

Mutlukent Mah Manuk Bey Sk No: 4

Çankaya, Ankara, 06800, Türkiye

Phone: +90 (312) 911 5735

Our Terms & Privacy Policy

Copyright - 2024 - Altai Inc - All rights reserved

Back to top Drag
  • Library
  • Articles
  • Patient Education
  • F.A.Q.
  • Contact Us

jghghjghjghhgj